The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. Sanofi […]readmore
Tags : Deal
Shots: RedHill regains exclusive WW rights for RHB-106 signed in 2014, encapsulated formulation for bowel preparation In 2014, RedHill signed a license agreement with Salix to commercialize RHB-106 in specific […]readmore
Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with […]readmore
Shots: The termination of 2014 deal with Samsung, is the result of Lusduna Nexvue’s sales and production costs. Samsung receives $155M as total termination cost including investment and interest on […]readmore